Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer

NCT04590560 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.

NCT NCT04590560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04590560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase
Not applicable
Overall status
Recruiting
Start date
February 6, 2020
Completion date
February 28, 2026
Enrollment
60,000 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer